

IMPACT FACTOR 4.5





an Open Access Journal by MDPI

# 10th Anniversary of Cancers—Targeted Therapies for Ovarian Cancer Treatment from Bench to Bedside

Guest Editors:

## Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### Prof. Dr. Robert Coleman

Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Deadline for manuscript submissions:

closed (31 December 2018)

# **Message from the Guest Editors**

Dear Colleagues,

This year, we are celebrating the 10<sup>th</sup> anniversary of our journal, *Cancers*. To date, the journal has published more than 1000 papers and the journal website attracts more than 60,000 monthly visits. The journal has a CiteScore 5.54 and is getting its first official impact factor this year. This milestone cannot be achieved without our readers, authors, peer reviewers, editors, and all the people working for the journal who have joined their tremendous efforts for years.

To mark this important milestone, a Special Issue entitled "10th Anniversary of *Cancers*—Targeted Therapies for Ovarian Cancer Treatment from Bench to Bedside" is being launched. This Special Issue collects high quality research articles and review papers on the topic related to the latest development of targeted cancer therapy in ovarian cancer. We kindly encourage all research groups to submit up-to-date, and comprehensive reviews and your research findings on this topic.

Prof. Dr. Samuel C. Mok Prof. Dr. Robert Coleman Guest Editors













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## **Contact Us**